CURRENT PHARMACEUTICAL DESIGN, vol.26, no.14, pp.1543-1555, 2020 (Peer-Reviewed Journal)
Article / Article
CURRENT PHARMACEUTICAL DESIGN
Science Citation Index Expanded, Scopus, Agricultural & Environmental Science Database, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
Micelles, D-alpha-tocopheryl polyethylene glycol succinate (TPGS), Pluronic F127, Pluronic F68, posaconazole, antifungal agent, ocular drug delivery, antifungal therapy, POLYMERIC MICELLES, NANOPARTICLES, NANOCARRIERS, ITRACONAZOLE, STRATEGIES, CARRIERS
Background: Topical therapy is preferred for the management of ocular fungal infections due to its superiorities which include overcoming potential systemic side effects risk of drugs, and targeting of drugs to the site of disease. However, the optimization of effective ocular formulations has always been a major challenge due to restrictions of ocular barriers and physiological conditions. Posaconazole, an antifungal and highly lipophilic agent with broad-spectrum, has been used topically as off-label in the treatment of ocular fungal infections due to its highly lipophilic character. Micellar carriers have the potential to improve the solubility of lipophilic drugs and, overcome ocular barriers.